Astellas Pharma Inc. buy melinda
Start price
26.03.18
/
50%
€12.63
Target price
05.04.18
€12.98
Performance (%)
4.02%
End price
05.04.18
€12.99
Summary
This prediction ended on 05.04.18 with a price of €12.99. The BUY prediction by melinda finished with a performance of 4.02%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Astellas Pharma Inc. | -0.305% | -0.305% | 22.800% | -19.769% |
| iShares Core DAX® | 0.794% | 2.841% | 22.630% | 72.985% |
| iShares Nasdaq 100 | 0.016% | -0.939% | 6.943% | 115.777% |
| iShares Nikkei 225® | 0.309% | -0.648% | 13.619% | 49.561% |
| iShares S&P 500 | 0.181% | -0.442% | 4.692% | 69.577% |
Comments by melinda for this prediction
In the thread Astellas Pharma Inc. diskutieren
SectorDrug Pharmaceuticals Agenda 28/03 Endgültige Dividende Detachment
Astellas Pharma Inc. und Seattle Genetics, Inc. (SGEN) haben bekannt gegeben, dass die US-amerikanische Gesundheitsbehörde Breakthrough Therapy für ein Antikörper-Wirkstoff-Konjugat, Vedotin-Konjugat, Patienten mit lokal fortgeschrittenem oder metastasierendem Urothelkarzinom, die zuvor behandelt wurden, gewährt hat Checkpoint-Inhibitoren.
Stopped prediction by melinda for Astellas Pharma Inc.
Astellas Pharma Inc.
Start price
Target price
Perf. (%)
€13.42
25.07.23
25.07.23
€16.00
25.07.24
25.07.24
-25.34%
26.07.24
26.07.24
Astellas Pharma Inc.
Start price
Target price
Perf. (%)
€45.42
17.11.13
17.11.13
€42.00
19.05.14
19.05.14
-81.45%
19.05.14
19.05.14
Astellas Pharma Inc.
Start price
Target price
Perf. (%)
€26.00
10.08.10
10.08.10
€33.00
10.02.11
10.02.11
12.27%
10.02.11
10.02.11